iBio Inc (IBIO)

[guay]

Another hurdle could be shortages of adjuvants, chemicals that are sometimes used to boost a vaccine’s immune response, experts said. Novavax, which has agreed to sell the U.S. government at least 100 million doses of its vaccine, reported earlier this month that its shot provoked a stronger immune response when coupled with an adjuvant in early-stage trials.
https://www.politico.com/news/2020/08/12/coronavirus-vaccine-challenges-394444

iBio is investigating an array of adjuvants in combination with iBio’s proprietary lichenase carrier molecule (“LicKMTM”) fused to a coronavirus subunit protein (“IBIO-201”) with the goal of producing a safe and effective vaccine for COVID-19 disease, and especially one for our most vulnerable populations, including the elderly. Ten distinct preclinical study arms for the IBIO-201 antigen-adjuvant combinations have been concluded. These include combinations delivered via intramuscular and intranasal routes, and datasets are under evaluation.

Company Overview
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.
#iBio $iBio iBio